Logo
x

Search

Subscribe Now

Recurrent

ONO and BMS' Opdivo + Yervoy Receive Approval for 1L Treatment for Unresectable Advanced or Recurrent Malignant Pleural Mesothelioma

ONO and BMS' Opdivo + Yervoy Receive Approval for 1L Treatment for Unresectable Advanced or Recurrent Malignant Pleural Mesothelio...

  • May 28, 2021
Lee's Pharma Socazolimab Receives NMPA's Breakthrough Therapy Designation for Treatment of Recurrent or Metastatic Cervical Cancer

Lee's Pharma Socazolimab Receives NMPA's Breakthrough Therapy Designation for Treatment of Recurrent or Metastatic Cervical Cancer

  • February 10, 2021
Merck's Keytruda (pembrolizumab) Receives the US FDA's Approval for Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma

Merck's Keytruda (pembrolizumab) Receives the US FDA's Approval for Patients with Recurrent or Metastatic Cutaneous Squamous Cell...

  • June 25, 2020
Merck KGaA's ERBITUX (cetuximab) Receives NMPA's Approval as a 1L treatment for Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck

Merck KGaA's ERBITUX (cetuximab) Receives NMPA's Approval as a 1L treatment for Recurrent/ Metastatic Squamous Cell Carcinoma of t...

  • March 2, 2020
Merck's Keytruda (pembrolizumab) Receives FDA's Approval as a Monotherapy for 1L+ Recurrent Locally Advanced or Metastatic Esophageal Cancer Expressing PD-L1 (CPS ≥10)

Merck's Keytruda (pembrolizumab) Receives FDA's Approval as a Monotherapy for 1L+ Recurrent Locally Advanced or Metastatic Esophag...

  • July 31, 2019
Roche's Rozlytrek (entrectinib) Receives MHLW's Approval for NTRK Fusion-Positive Advanced Recurrent Solid Tumors in Adult and Pediatric Patients in Japan

Roche's Rozlytrek (entrectinib) Receives MHLW's Approval for NTRK Fusion-Positive Advanced Recurrent Solid Tumors in Adult and Ped...

  • June 18, 2019
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.